Stay updated with breaking news from Patrick Barth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the immunocompromised.1-3Three
F. Hoffmann-La Roche Ltd: FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes need for new treatment options 1 Ib This is the 11th Breakthrough Therapy Designation for Roche's haematology Venclexta demonstrating its potential across multiple blood cancers Basel, 21 July 2021 - Roche] study is a phase Ib, open-label, non-randomised, multicentre, dose-finding study evaluating Venclexta/Venclyxto (venetoclax) in combination with azacitidine in treatment-naïve patients with higher-risk myelodysp...
F. Hoffmann-La Roche Ltd: Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 casirivimab hospitalised patients Basel, 20 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve(casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. "Ronapreve ha...
) Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins involved in the natural coagulation cascade, and restore the blood clotting process for people with haemophilia A. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once-weekly, every two weeks or every four weeks (after an initial once-weekly dose for the first four weeks). Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed g...
F. Hoffmann-La Roche Ltd: New data for Roche's Hemlibra reinforce safety profile in people with haemophilia A IIIb haemophilia Hemlibra 1 STASEY is one of the largest open-label studies primarily assessing safety and tolerability of a medicine for people with haemophilia Hemlibra also continued to demonstrate effective bleed control with a high proportion of participants (82.6%) achieving zero treated bleeds 1 Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of...